Skip to content

A Monocentric Study Evaluating Pupillometry as an Objective Measurement for CI Fittings

A Monocentric Study Evaluating Pupillometry as an Objective Measurement for Cochlear Implant (CI) Fittings

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05586555
Acronym
PupillOM
Enrollment
13
Registered
2022-10-19
Start date
2023-05-02
Completion date
2023-11-06
Last updated
2024-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cochlear Hearing Loss, Hearing Loss, Bilateral, Hearing Loss, Cochlear, Hearing Loss, Sensorineural

Keywords

Cochlear Implant system

Brief summary

This trial is a monocentric, prospective and controlled study of the pupil response to detect hearing threshold and comfortable loudness of normal-hearing (NH) and CI-subjects.

Detailed description

The purpose of the clinical investigation is to explore the pupil dilation response of subjects with a cochlear implant and to provide proof of concept that it is possible to perform the adaptation of a cochlear implant using pupillometry. The population of this study is divided in 2 group: * A control group with normal-hearing listeners. * An Cl group with subjects with bilateral, severe-to-profound sensorineural hearing loss, with at least one cochlear implant for more than 6 months. Mainly used in audiology to evaluate listening effort, pupillometry is an objective measure that could also be used for fittings. Studies have shown that sound intensity influence pupil dilation. indeed, normal hearing and hearing aids subjects exhibit larger pupil responses with increasing intensity/loudness. The purpose of this study is to explore the pupil dilation response of cochlear implant subjects and to provide a proof of concept that we can perform cochlear implant fitting using pupillometry. Implanted subjects (Cl group) will undergo up to 3 visits: 1. Visit 1 or V1(inclusion) on day 1, 2. Visit 2 or V2 (Experiment 1-+2+3 or Experiment 1+2 or Experiment 3 )\* up to 1 month after V1 3. Visit 3 or V3 (Experiment 1+2 or Experiment 3, optional)\* up to 1 month after V2 \*lt is up to investigator decision to conduct experiment 1+2 and experiment 3 the same day or in on independent visit (no matter in which order) Normal-hearing listeners (control group) will undergo up to 2 visits: 1. Visit 1 or Va (inclusion) on day 1, 2. Visit 2 or V2 (experiment) up to 1 month after V1

Interventions

OTHERPupillometry (Eve-tracking measurements)

Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.

Sponsors

Oticon Medical
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

A control group with normal hearing subjects versus a CI group with cochlear implanted subjects.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Both groups: * Adult (≥ 18 years old) * Fluent in French language * Affiliation to social security * Information and signature of a written consent prior to any study-specific procedure * Control group (normal hearing in regards of age): • Normal hearing participants according to pure tone hearing levels defined for age and tested frequency (audiometry ISO 7029 and Wand & Puel, 2020 recommendations for hearing loss at the tested frequencies) * CI group (cochlear implant subjects): * Bilateral, severe-to-profound sensorineural hearing loss, with at least one cochlear implant system * Using Oticon Medical Neuro Cochlear Implant System (NCIS) or Digisonic Cochlear Implant system (DCIS), unilateral or bilateral * Duration of cochlear implant experience ≥ 6 months (period from cochlear implant activation to study enrolment) * Pure Tone Audiometry must be strictly below 50 dBA, CI aided.

Exclusion criteria

* Both groups, according to the best practices for pupillometry (Winn et al., 2018): * Eye diseases: nystagmus, amblyopia, and macular degeneration * Severe head injury or any history of significant neurological problems: These issues can affect gaze stability, congruence of eye movements, and pupil dilation * Concomitant medication that can impact the parasympathetic autonomic nervous system * Person under State Medical Assistance (AME for Aide medical d'état in French) * Use of one of the following treatments: Trihexyphenidyl, Biperiden or Tropatepine (anticholinergics, commonly used in the treatment of Parkinson's disease) * Person under legal protection (guardianship, curators, other, etc.) or under family authorization * Unwillingness or inability to comply with all investigational requirements * Additional cognitive, medical, or social handicaps that would prevent completion of all study requirements

Design outcomes

Primary

MeasureTime frameDescription
Measurement of the pupil dilation response to a range of auditory stimuli (acoustic and electric).At Visit 2 (Month 1)Pupil dilation response for each intensity and frequency \[Mean pupil dilatation in milimeters\]

Secondary

MeasureTime frameDescription
Evaluation of the loudness perception of the subjects regarding the different auditory stimuli (acoustic and electric) to correlate the results to the pupil dilation response.At Visit 2 (Month 1) and Visit 3 (Month 2)* [* if done]Loudness score corresponding to each pupil dilation response. \[Using Oticon Medical Loudness scale: scale from 0 to 10 following the ISO 16832. 0 (zero) corresponding to inaudible level and 10 to extremely loud (intolerable) sounds.\]

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026